Michael C Wallace1,2,3, Matthew Knuiman4, Yi Huang5, George Garas6,5, Leon A Adams6,5, Gerry MacQuillan6,5, David B Preen4, Gary P Jeffrey6,5. 1. Department of Hepatology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, WA, 6009, Australia. michael.wallace2@health.wa.gov.au. 2. School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA, Australia. michael.wallace2@health.wa.gov.au. 3. School of Population and Global Health, University of Western Australia, Nedlands, WA, Australia. michael.wallace2@health.wa.gov.au. 4. School of Population and Global Health, University of Western Australia, Nedlands, WA, Australia. 5. School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA, Australia. 6. Department of Hepatology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Perth, WA, 6009, Australia.
Abstract
BACKGROUND AND AIMS: There has been significant debate regarding which hepatocellular carcinoma (HCC) staging system is best able to predict survival. We hypothesized that the prognostic ability of the Barcelona Clinic Liver Cancer (BCLC) and Hong Kong Liver Cancer (HKLC) systems would be improved with the addition of an explicit treatment variable. METHODS: We performed an analysis of a prospectively enrolled cohort of 292 patients undergoing 532 treatment episodes for HCC from 2006 to 2014. BCLC, standard nine-stage HKLC (HKLC9), and modified five-stage HKLC (HKLC5) for each treatment episode were assessed. Overall survival and time to disease progression were calculated for the initial treatment, re-treatment, and overall treatment cohorts. We compared the performance of various prognostic models including staging system alone, treatment alone, and staging system plus treatment using the corrected Akaike information criterion and Harrell's C statistic. RESULTS: The BCLC, HKLC5, and HKLC9 systems were significant predictors of survival and time to progression for all treatment cohorts (log rank test, p < 0.001). The addition of a treatment variable significantly improved (p < 0.01) the prognostic ability of the survival and time to progression models compared with those containing only the BCLC or HKLC stage across all treatment cohorts other than survival in re-treatment for BCLC (p = 0.094). CONCLUSIONS: Adding a treatment variable to major HCC staging systems improves their ability to predict survival and time to progression in initial treatment, re-treatment, and overall.
BACKGROUND AND AIMS: There has been significant debate regarding which hepatocellular carcinoma (HCC) staging system is best able to predict survival. We hypothesized that the prognostic ability of the Barcelona Clinic Liver Cancer (BCLC) and Hong Kong Liver Cancer (HKLC) systems would be improved with the addition of an explicit treatment variable. METHODS: We performed an analysis of a prospectively enrolled cohort of 292 patients undergoing 532 treatment episodes for HCC from 2006 to 2014. BCLC, standard nine-stage HKLC (HKLC9), and modified five-stage HKLC (HKLC5) for each treatment episode were assessed. Overall survival and time to disease progression were calculated for the initial treatment, re-treatment, and overall treatment cohorts. We compared the performance of various prognostic models including staging system alone, treatment alone, and staging system plus treatment using the corrected Akaike information criterion and Harrell's C statistic. RESULTS: The BCLC, HKLC5, and HKLC9 systems were significant predictors of survival and time to progression for all treatment cohorts (log rank test, p < 0.001). The addition of a treatment variable significantly improved (p < 0.01) the prognostic ability of the survival and time to progression models compared with those containing only the BCLC or HKLC stage across all treatment cohorts other than survival in re-treatment for BCLC (p = 0.094). CONCLUSIONS: Adding a treatment variable to major HCC staging systems improves their ability to predict survival and time to progression in initial treatment, re-treatment, and overall.
Entities:
Keywords:
Cancer progression; Cancer staging; Cancer survival; Hepatocellular carcinoma
Authors: Ju Dong Yang; Joseph J Larson; Kymberly D Watt; Alina M Allen; Russell H Wiesner; Gregory J Gores; Lewis R Roberts; Julie A Heimbach; Michael D Leise Journal: Clin Gastroenterol Hepatol Date: 2016-12-21 Impact factor: 11.382
Authors: Roberta De Angelis; Milena Sant; Michel P Coleman; Silvia Francisci; Paolo Baili; Daniela Pierannunzio; Annalisa Trama; Otto Visser; Hermann Brenner; Eva Ardanaz; Magdalena Bielska-Lasota; Gerda Engholm; Alice Nennecke; Sabine Siesling; Franco Berrino; Riccardo Capocaccia Journal: Lancet Oncol Date: 2013-12-05 Impact factor: 41.316
Authors: Philip J Johnson; Sarah Berhane; Chiaki Kagebayashi; Shinji Satomura; Mabel Teng; Helen L Reeves; James O'Beirne; Richard Fox; Anna Skowronska; Daniel Palmer; Winnie Yeo; Frankie Mo; Paul Lai; Mercedes Iñarrairaegui; Stephen L Chan; Bruno Sangro; Rebecca Miksad; Toshifumi Tada; Takashi Kumada; Hidenori Toyoda Journal: J Clin Oncol Date: 2014-12-15 Impact factor: 44.544
Authors: Fabio Farinati; Alessandro Vitale; Gaya Spolverato; Timothy M Pawlik; Teh-la Huo; Yun-Hsuan Lee; Anna Chiara Frigo; Anna Giacomin; Edoardo G Giannini; Francesca Ciccarese; Fabio Piscaglia; Gian Lodovico Rapaccini; Mariella Di Marco; Eugenio Caturelli; Marco Zoli; Franco Borzio; Giuseppe Cabibbo; Martina Felder; Rodolfo Sacco; Filomena Morisco; Elisabetta Biasini; Francesco Giuseppe Foschi; Antonio Gasbarrini; Gianluca Svegliati Baroni; Roberto Virdone; Alberto Masotto; Franco Trevisani; Umberto Cillo Journal: PLoS Med Date: 2016-04-26 Impact factor: 11.069